Spots Global Cancer Trial Database for Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Official Title: Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Study ID: NCT04300062
Conditions
Interventions
Study Description
Brief Summary: The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
Detailed Description: The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, , France
Contact Details
Name: Etienne Giroux Leprieur, MD, PhD
Affiliation: Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
